Evidence map›Paper›PMID 28733033›Full record

ArticleBiochemical and biophysical research communications2017

Discovery of small molecule inhibitors for the C. elegans caspase CED-3 by high-throughput screening.

Scott J Brantley, Steven W Cotten, David R Lamson, Ginger R Smith, Rihe Liu, Kevin P Williams

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Scott J BrantleyDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Steven W CottenDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
David R LamsonBiomanufacturing Research Institute and Technology Enterprise, Durham, NC 27707, USA.
Ginger R SmithBiomanufacturing Research Institute and Technology Enterprise, Durham, NC 27707, USA.
Rihe LiuDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA; Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: rihe_liu@unc.edu.
Kevin P WilliamsBiomanufacturing Research Institute and Technology Enterprise, Durham, NC 27707, USA; Department of Pharmaceutical Sciences, North Carolina Central University, Durham, NC 27707, USA. Electronic address: kpwilliams@nccu.edu.
University of North Carolina at Chapel Hill · USNorth Carolina Central University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Identification of Caspase Substrates from Human ProteomeR01NS047650 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, RIHE · 2004 to 2008
$1.4M
NCI NIH HHS P30 CA016086NINDS NIH HHS R01 NS047650
6 · The paper itself

Abstract

C. elegans has been widely used as a model organism for programmed cell death and apoptosis. Although the CED-3 caspase is the primary effector of cell death in C. elegans, no selective inhibitors have been identified. Utilizing high-throughput screening with recombinant C. elegans CED-3 protein, we have discovered and confirmed 21 novel small molecule inhibitors. Six compounds had IC

Indexed as

Caenorhabditis elegans ProteinsCaspase InhibitorsCaspasesDrug DiscoveryDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysMolecular WeightCaenorhabditis elegans ProteinsCaspase InhibitorsCaspasesced-3 protein, C elegansApoptosisCaspaseCED-3C. elegansHigh-throughput screeningSmall molecule inhibitor

Identifiers

PMID28733033
PMCPMC5590106
OpenAlexW2738524404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.